" class="no-js "lang="en-US"> Carolyn Magill - Medtech Alert
Tuesday, September 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Carolyn Magill

Carolyn Magill

About Carolyn Magill

Specialties: Health care, real world evidence, value-based care, outcomes-based contracting, supporting scalability, developing people, strategy, operations, Medicaid, Medicare, long term care, provider network strategy, product development, legislative advocacy, pay for performance, accountable care, health insurance.

Related Story

Industry News

 Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization | Pharmtech Focus

Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization

August 2 2021

Syneos Health® (Nasdaq:SYNH) and Aetion® announced a partnership to provide regulatory-grade data and analytics-driven solutions to advance […]